Latest Conference Articles

Biosimilar Pegfilgrastim Savings Aid More Patients in Models Presented at ASCO

Skylar Jeremias

June 1 2020

Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study

Skylar Jeremias

May 31 2020

When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

Rituximab Biosimilar Demonstrates Similarity in ASCO Study

Tony Hagen

May 31 2020

The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

US Needs Drug Negotiating Power, ASCO Study Concludes

Skylar Jeremias

May 31 2020

Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation at the American Society of Clinical Oncology.

Higher Value Oncology Care Is Needed, VA Doctor Says at ASCO

Tony Hagen

May 30 2020

Devika Das, MBBS, reviews the evidence presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, and concludes that some deep reforms are needed in oncology care to improve access.

Money and Control Influence Oncologists' Use of Biosimilars

Skylar Jeremias

May 30 2020

Abstracts presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology, revealed important data on physician prescribing of biosimilars and cost savings in the oncology space.

Prestige BioPharma's Trastuzumab Demonstrates Equivalence

Tony Hagen

May 29 2020

Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab, based on findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.

Biosimilar Pegfilgrasim Cuts OCM Expense, ASCO Study Finds

Tony Hagen

May 29 2020

A study presented at ASCO20 Virtual demonstrated the power of biosimilar pegfilgrastim to lower costs in the Oncology Care Model (OCM), where pegfilgrastim expense amounts to 5.3% of the total cost of cancer care.

Part 1: NCCN Panelist Says Biosimilar Past Is Not Prologue

Skylar Jeremias

May 28 2020

Despite the United States’ slow start in biosimilar uptake, history shows that things can change, according to Michael Kolodziej, MD, who presented at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Conference.

Part II: NCCN Panelists Take On Drug Rebates

Tony Hagen

May 22 2020

Drug rebates have survived despite the payment reforms imposed by the Medicare Modernization Act of 2003, and now payers are taking advantage of them, too, panelists noted at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.